Effects of combined sacubitril and empagliflozin therapy on hemodynamic and hemorheological parameters in patients with chronic heart failure
Abstract
Chronic heart failure (CHF) is characterized by progressive hemodynamic deterioration, neurohormonal activation, and hemorheological imbalance. Optimization of arterial pressure, heart rate, and coagulation status is essential for improving prognosis. To evaluate the effects of combined sacubitril and empagliflozin therapy on hemodynamic and hemorheological parameters in patients with CHF. A total of 43 patients with CHF were assessed before and after treatment. Systolic and diastolic blood pressure (SBP/DBP), heart rate (HR), and blood coagulation parameters (Sukharev method) were analyzed.Significant reductions in SBP (−9.87 mmHg, p=0.0227) and DBP (−5.97 mmHg, p=0.0059) were observed. HR decreased by 7.72 beats/min (p=0.010). Coagulation initiation time increased significantly (p=0.003), indicating reduced hypercoagulability. Combined sacubitril and empagliflozin therapy significantly improves hemodynamic stability and reduces thrombotic risk in CHF patients.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.